These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37973643)

  • 1. Nanoparticle-Based Approaches for Treatment of Hematological Malignancies: a Comprehensive Review.
    Hani U; Gowda BHJ; Haider N; Ramesh K; Paul K; Ashique S; Ahmed MG; Narayana S; Mohanto S; Kesharwani P
    AAPS PharmSciTech; 2023 Nov; 24(8):233. PubMed ID: 37973643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.
    de la Puente P; Azab AK
    Eur J Haematol; 2017 Jun; 98(6):529-541. PubMed ID: 28208215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine strategies for hematological malignancies: what is next?
    Visani G; Loscocco F; Isidori A
    Nanomedicine (Lond); 2014 Oct; 9(15):2415-28. PubMed ID: 25413858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
    Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger KG; Jönsson PE; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
    Acta Oncol; 2001; 40(2-3):135-54. PubMed ID: 11441927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.
    Ye Q; Lin Y; Li R; Wang H; Dong C
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):607-623. PubMed ID: 35339668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Drug Delivery for the Treatment of Blood Cancers.
    Jiang Y; Lin W; Zhu L
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in silica based nanoparticles for targeted cancer therapy.
    Yang Y; Yu C
    Nanomedicine; 2016 Feb; 12(2):317-32. PubMed ID: 26706409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines.
    Hazan-Halevy I; Landesman-Milo D; Rosenblum D; Mizrahy S; Ng BD; Peer D
    J Control Release; 2016 Dec; 244(Pt B):149-156. PubMed ID: 27491881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymeric nanomedicines targeting hematological malignancies.
    Gu W; Qu R; Meng F; Cornelissen JJLM; Zhong Z
    J Control Release; 2021 Sep; 337():571-588. PubMed ID: 34364920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches for reducing chemo/radiation-induced cardiotoxicity by nanoparticles.
    Li K; Chen W; Ma L; Yan L; Wang B
    Environ Res; 2024 Mar; 244():117264. PubMed ID: 37776941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight on nano drug delivery systems with targeted therapy in treatment of oral cancer.
    Vyas K; Rathod M; Patel MM
    Nanomedicine; 2023 Apr; 49():102662. PubMed ID: 36746272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine - a promising therapy for hematological malignancies.
    Huang L; Huang J; Huang J; Xue H; Liang Z; Wu J; Chen C
    Biomater Sci; 2020 May; 8(9):2376-2393. PubMed ID: 32314759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Hybrid Vesicular-based Drug Delivery Systems: Improved Biocompatibility, Targeting, Therapeutic Efficacy and Pharmacokinetics of Anticancer Drugs.
    Setia A; Sahu RK; Ray S; Widyowati R; Ekasari W; Saraf S
    Curr Drug Metab; 2022; 23(9):757-780. PubMed ID: 35761494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noble metal nanomaterials for the diagnosis and treatment of hematological malignancies.
    Huang X; Mahmudul HM; Li Z; Deng X; Su X; Xiao Z; Zhao L; Liu T; Li H
    Front Biosci (Landmark Ed); 2022 Jan; 27(2):40. PubMed ID: 35226983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in targeted gene silencing and cancer therapy by nanoparticle-based delivery systems.
    Liu H; Zhu X; Wei Y; Song C; Wang Y
    Biomed Pharmacother; 2023 Jan; 157():114065. PubMed ID: 36481408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Perspectives on Nanoparticle-based Targeted Drug Delivery Approaches in Breast Cancer Treatment.
    Pandey P; Khan F; Maqsood R; Upadhyay TK
    Endocr Metab Immune Disord Drug Targets; 2023; 23(10):1291-1302. PubMed ID: 36924095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: A systematic review.
    Salari N; Mansouri K; Valipour E; Abam F; Jaymand M; Rasoulpoor S; Dokaneheifard S; Mohammadi M
    Daru; 2021 Dec; 29(2):439-447. PubMed ID: 34499323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.